Evidence map›Paper›PMID 34771026›Full record

ArticleMolecules (Basel, Switzerland)2021

Robust Saliva-Based RNA Extraction-Free One-Step Nucleic Acid Amplification Test for Mass SARS-CoV-2 Monitoring.

Eva Rajh, Tina Šket, Arne Praznik, Petra Sušjan, Alenka Šmid, Dunja Urbančič, Irena Mlinarič-Raščan, Polona Kogovšek, Tina Demšar, Mojca Milavec and 8 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 1 country.

Eva RajhDepartment of Synthetic Biology and Immunology, National Institute of Chemistry, SI-1001 Ljubljana, Slovenia.
Tina ŠketDepartment of Synthetic Biology and Immunology, National Institute of Chemistry, SI-1001 Ljubljana, Slovenia.
Arne PraznikDepartment of Synthetic Biology and Immunology, National Institute of Chemistry, SI-1001 Ljubljana, Slovenia.
Petra SušjanDepartment of Synthetic Biology and Immunology, National Institute of Chemistry, SI-1001 Ljubljana, Slovenia.ORCID 0000-0002-0133-9896
Alenka ŠmidFaculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia.
Dunja UrbančičFaculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia.
Irena Mlinarič-RaščanFaculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia.
Polona KogovšekDepartment of Biotechnology and Systems Biology, National Institute of Biology, SI-1000 Ljubljana, Slovenia.ORCID 0000-0002-4035-0115
Tina DemšarDepartment of Biotechnology and Systems Biology, National Institute of Biology, SI-1000 Ljubljana, Slovenia.
Mojca MilavecDepartment of Biotechnology and Systems Biology, National Institute of Biology, SI-1000 Ljubljana, Slovenia.ORCID 0000-0002-5794-2109
Katarina Prosenc TrilarNational Laboratory of Health, Environment, and Food, Laboratory for Public Health Virology, SI-1000 Ljubljana, Slovenia.
Žiga JensterleNational Laboratory of Health, Environment, and Food, Laboratory for Public Health Virology, SI-1000 Ljubljana, Slovenia.
Mihaela ZidarnEmergency Service, Health Centre Jesenice, SI-4270 Jesenice, Slovenia.ORCID 0000-0003-0515-5207
Viktorija TomičUniversity Clinic of Respiratory and Allergic Diseases, SI-4204 Golnik, Slovenia.
Gabriele TurelDepartment for Infectious Diseases, University Medical Center Ljubljana, SI-1000 Ljubljana, Slovenia.
Tatjana Lejko-ZupancDepartment for Infectious Diseases, University Medical Center Ljubljana, SI-1000 Ljubljana, Slovenia.
Roman JeralaDepartment of Synthetic Biology and Immunology, National Institute of Chemistry, SI-1001 Ljubljana, Slovenia.
Mojca BenčinaDepartment of Synthetic Biology and Immunology, National Institute of Chemistry, SI-1001 Ljubljana, Slovenia.
National Institute of Chemistry · SIUniversity of Ljubljana · SINational Institute of Biology · SILjubljana University Medical Centre · SINational Laboratory of Health, Environment and Food · SIAngela Boškin Faculty of Health Care · SIEN-FIST Centre of Excellence (Slovenia) · SIUniversity Clinic of Pulmonary and Allergic Diseases Golnik · SI

Funding

Slovenian research agency P1-0208Slovenian research agency P4-0165Slovenian research agency P4-0176Slovenian research agency P4-0407Slovenian research agency V4-2038
6 · The paper itself

Abstract

Early diagnosis with rapid detection of the virus plays a key role in preventing the spread of infection and in treating patients effectively. In order to address the need for a straightforward detection of SARS-CoV-2 infection and assessment of viral spread, we developed rapid, sensitive, extraction-free one-step reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and reverse transcription loop-mediated isothermal amplification (RT-LAMP) tests for detecting SARS-CoV-2 in saliva. We analyzed over 700 matched pairs of saliva and nasopharyngeal swab (NSB) specimens from asymptomatic and symptomatic individuals. Saliva, as either an oral cavity swab or passive drool, was collected in an RNA stabilization buffer. The stabilized saliva specimens were heat-treated and directly analyzed without RNA extraction. The diagnostic sensitivity of saliva-based RT-qPCR was at least 95% in individuals with subclinical infection and outperformed RT-LAMP, which had at least 70% sensitivity when compared to NSBs analyzed with a clinical RT-qPCR test. The diagnostic sensitivity for passive drool saliva was higher than that of oral cavity swab specimens (95% and 87%, respectively). A rapid, sensitive one-step extraction-free RT-qPCR test for detecting SARS-CoV-2 in passive drool saliva is operationally simple and can be easily implemented using existing testing sites, thus allowing high-throughput, rapid, and repeated testing of large populations. Furthermore, saliva testing is adequate to detect individuals in an asymptomatic screening program and can help improve voluntary screening compliance for those individuals averse to various forms of nasal collections.

Indexed as

COVID-19COVID-19 TestingHumansMass ScreeningNucleic Acid Amplification TechniquesReverse Transcriptase Polymerase Chain ReactionRNARNA, ViralSalivaSARS-CoV-2Sensitivity and SpecificitySpecimen HandlingRNARNA, ViralCOVID-19LAMPoral cavity swabpassive droolpoolingRT-qPCRsalivaSARS-CoV-2

Identifiers

PMID34771026
PMCPMC8588466
OpenAlexW3209532377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.